GlassScriptPhysician profile
Conley W Engstrom
NPI 1518949551
$13,417.91
in general payments reported to CMS, 2019-2025
29 companies · $1,494 in 2025
The $1,494 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,368 · 2020: $396 · 2021: $1,754 · 2022: $1,361 · 2023: $4,504 · 2024: $2,541 · 2025: $1,494.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,524 · Consulting Fee: $2,800 · Travel and Lodging: $124 · Education: $89.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,524.06 |
| Consulting Fee | $2,800.00 |
| Travel and Lodging | $124.45 |
| Education | $89.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $3,594.74 | 2019-2025 | Ilumya, Absorica Ld, Winlevi |
| Galderma Laboratories, L.P. | $1,833.37 | 2019-2025 | Nemluvio, Aklief |
| Journey Medical Corporation | $1,219.44 | 2019-2025 | |
| Janssen Biotech, INC. | $1,204.61 | 2019-2025 | Tremfya, Remicade, Stelara |
| E.R. Squibb & Sons, L.L.C. | $813.65 | 2023-2025 | Sotyktu |
| Abbvie INC. | $719.48 | 2019-2025 | |
| Dermavant Sciences, INC. | $706.86 | 2022-2024 | Vtama |
| Lilly USA, LLC | $569.02 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Novartis Pharmaceuticals Corporation | $483.58 | 2019-2025 | |
| Pfizer INC. | $299.43 | 2019-2024 | |
| Incyte Corporation | $274.77 | 2023-2025 | Opzelura |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $260.11 | 2021-2024 | Cabtreo |
| Ucb, INC. | $223.15 | 2021-2025 | Bimzelx |
| Leo Pharma INC. | $189.72 | 2019-2024 | Adbry |
| Amgen INC. | $166.59 | 2021-2025 | Otezla, Otezla |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $157.02 | 2019-2023 | Seysara |
| Regeneron Healthcare Solutions, INC. | $149.95 | 2023-2025 | Libtayo |
| Arcutis Biotherapeutics, INC. | $98.16 | 2023-2024 | Zoryve |
| Organon LLC | $86.55 | 2025 | Vtama, Nexplanon |
| Mayne Pharma Commercial LLC | $64.51 | 2024-2025 | |
| Genzyme Corporation | $62.06 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $58.22 | 2019-2023 | Keytruda |
| Kyowa Kirin, INC. | $54.60 | 2024-2025 | Poteligeo |
| Verrica Pharmaceuticals INC. | $33.49 | 2024 | Ycanth |
| Genentech USA, INC. | $27.36 | 2019-2020 | |
| Ani Pharmaceuticals, INC. | $22.79 | 2023 | Veregen |
| Epi Health, LLC | $18.54 | 2022 | |
| Organogenesis INC. | $13.31 | 2020 | |
| Taro Pharmaceuticals USA, INC. | $12.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Conley Engstrom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.